-
link
Presented Preclinical Data on GNTbm-38, an Novel Epigenetic Immune Activator, at the 2025 ASCO Annual Meeting
Announced the preclinical data on GNTbm-38, an novel epigenetic immune activator for cancer immunotherapy. GNTbm-38 was presented as posters at the 2025 American Association of Clinical Oncology (ASCO) Annual Meeting, which is held in Chicago, USA, from May 30 to Jun 04, 2025.
Abstract: 2574
Title: Preclinical development of GNTbm-38, a novel class I histone deacetylase inhibitor, while combined with anti-VEGFR TKI or anti-PD-1 Ab: Assessment of immune activation and immune memory in cancer immunotherapy.
Session Date/Time: 6/2/2025, 1:30 PM-4:30 PM CT
Poster Board Number: 221
2025-05-23
-
link
GNTbm’s Trial on New Epigenetic Drug Generates Hope for Patients with Breast Cancer
GNTbm’s Trial on New Epigenetic Drug Generates Hope for Patients with Breast Cancer.
2021-07-23
-
link
GNTbm announces licensing of exclusive sales/marketing rights of anticancer drug Chidamide to Taiwan Specialty Pharma Corp. (TSPC)
GNT Biotech & Medicals Co., Ltd. (GNTbm, TPEx Emerging: 7427) announced that it has awarded exclusive sales and marketing rights in Taiwan of anticancer drug Chidamide to pharmaceutical distribution company Taiwan Specialty Pharma Corp. (TSPC)
2018-06-21
-
link
GNTbm to begin Phase III clinical trial in Taiwan of Chidamide for breast cancer
GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer
2017-04-19
-
link
GNTbm Exhibits at the 2016 BIO
GNTbm Exhibits at the 2016 BIO
2016-06-04
-
link
GNTbm Updates Developments in the Vaucarrin® Nanogold Drug Delivery Platform
GNTbm Updates Developments in the Vaucarrin® Nanogold Drug Delivery Platform
2015-09-01
